Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global leader in medical technology, headquartered in Plainsboro, New Jersey. Established in 1989, Integra is dedicated to reducing uncertainty for surgeons, allowing them to focus on providing outstanding patient care. The company offers innovative solutions in various medical fields including orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
Integra's diverse portfolio includes products for regenerative therapy, extremity orthopedics, and neurosurgical applications. Their orthopedic product line features devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. The company is also a key player in the neurosurgery market, offering a broad range of implants, devices, instruments, and systems used in neurosurgery, neuromonitoring, neurotrauma, and critical care.
Integra operates through two main segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical segment generates the majority of the company's revenue, focusing on neurosurgical and surgical instrumentation. The Tissue Technologies segment covers regenerative and advanced wound care products.
With over 3,500 employees worldwide, Integra serves markets in Europe, the Asia-Pacific region, and other parts of the globe, although the bulk of its revenue comes from domestic sales. Recently, the company announced its second-quarter 2023 financial results, highlighting a total revenue of $381.3 million, a slight decline compared to the previous year, primarily due to a recall issue at their Boston manufacturing facility. Despite this, the company showed resilience with strong performances in certain product lines and updated their guidance for 2023 revenue and earnings per share.
Integra's recent acquisition of Acclarent, a leader in ENT procedures, for $275 million, showcases their ongoing commitment to expanding their product offerings and improving healthcare outcomes. This acquisition is expected to close by the second quarter of 2024 and will significantly bolster Integra's position in the ENT market.
Integra continues to develop and launch groundbreaking products such as the CereLink ICP Monitoring System for intracranial pressure monitoring and the MicroMatrix Flex, which addresses complex wound reconstruction needs. These innovations reflect Integra's dedication to advancing surgical, neurologic, and regenerative care standards.
For the latest updates and further information, visit www.integralife.com.
A new economic study published in the Journal of Comparative Effectiveness Research demonstrates significant cost savings when using Integra's DuraSeal Polyethylene Glycol (PEG) hydrogel instead of fibrin glue in posterior cranial fossa surgeries. The analysis, conducted across five European countries (Belgium, France, Germany, Italy, and UK), shows cost savings ranging from €419 to €1,279 per patient, representing an average 22% cost reduction per procedure (15% in Italy).
The study is based on a prospective observational study of 200 patients and reveals that DuraSeal's effectiveness at preventing cerebrospinal fluid (CSF) leaks leads to reduced hospital stays and fewer post-surgical interventions. Despite higher upfront costs, DuraSeal proves to be a cost-effective alternative to fibrin glue in PCF surgery across European healthcare systems.
Integra LifeSciences (NASDAQ: IART) reported Q3 2024 financial results with revenues of $380.8 million, showing a 0.4% decrease on a reported basis and 8.6% decline organically compared to last year. The company posted a GAAP loss of $(0.14) per share, down from $0.24 in the prior year, while adjusted EPS fell to $0.41 from $0.76.
The Codman Specialty Surgical segment (~70% of revenues) reached $270.8 million with 1.0% reported growth, while Tissue Technologies (~30%) declined 3.6% to $110.1 million. The company updated its full-year 2024 guidance to $1.609-1.619 billion in revenue and adjusted EPS of $2.41-2.49.
Integra LifeSciences (NASDAQ: IART) has appointed Mojdeh Poul as its new president and CEO, effective January 6, 2025. Poul, who previously served as executive vice president and group president of 3M's $8.5B Global Healthcare Business, will succeed Jan De Witte. She brings extensive experience in healthcare business strategy, portfolio transformation, and commercial operations. Poul's background includes leadership positions at Medtronic and Boston Scientific, and she currently serves on the boards of Align Technology, iRhythm Technologies, and Stanley Black & Decker. Stuart Essig will temporarily serve as executive chairman before returning to his non-executive chairman role.
Integra LifeSciences Holdings (NASDAQ: IART), a leading global medical technology company, has announced it will release its third quarter 2024 financial results on Monday, November 4, 2024, before the market opens. Following the release, the company's management team will host a conference call at 8:30 a.m. ET to discuss the results.
Investors and interested parties can access a live webcast of the conference call through the Investors section of Integra's website at investor.integralife.com. Those planning to participate in the call are encouraged to register in advance to receive dial-in details and an individual pin. It is recommended to join the call 10 minutes before it starts. A webcast replay of the conference call will be made available on the company's Investors section following the event.
Halda Therapeutics, a biotech company developing RIPTAC™ (Regulated Induced Proximity TArgeting Chimeras) therapeutics for cancer, has appointed Christian Schade as President, CEO, and Board member. Schade brings over 20 years of pharma and biotech industry experience, including leadership in clinical pipeline development and value-creating deals. Tim Shannon continues as Board Chairman.
Schade's appointment comes as Halda prepares to enter clinical trials, with the first RIPTAC therapeutic expected to begin trials in the first half of 2025. The company is focusing on developing therapies for prostate and breast cancer. Schade's previous roles include CEO of Aprea Therapeutics, Growth Partner at Flagship Pioneering, and executive positions at Novira, Omthera Pharmaceuticals, and Medarex.
Integra LifeSciences (NASDAQ: IART), a leading global medical technology company, has announced its participation in the 22nd Annual Morgan Stanley Healthcare Conference. Lea Knight, the company's chief financial officer, is scheduled to present on September 6, 2024, at 10:45am ET.
The presentation will be accessible via a live webcast on Integra LifeSciences' investor relations website. This event provides an opportunity for investors and analysts to gain insights into the company's recent developments, financial performance, and future outlook within the healthcare technology sector.
Integra LifeSciences' participation in this prestigious conference underscores its commitment to engaging with the investment community and showcasing its position in the medical technology market.
Integra LifeSciences (NASDAQ: IART), a global medical technology leader, has announced its participation in the 2024 Wells Fargo Healthcare Conference. Lea Knight, the company's chief financial officer, is scheduled to present on September 4, 2024, at 1:30 PM ET.
Investors and interested parties can access a live webcast of the presentation through Integra's investor relations website. This event provides an opportunity for stakeholders to gain insights into the company's current status and future prospects directly from its financial leadership.
The presentation at this prestigious healthcare conference underscores Integra's commitment to transparency and engagement with the investment community, potentially impacting its market position and stock performance.
Integra LifeSciences (NASDAQ: IART) has released its third Environmental, Social and Governance (ESG) report, highlighting the company's 2023 performance and ongoing efforts in line with its ESG strategy. Key achievements include:
Environmental: Recalculated Scope 1, 2, and 3 emissions and partnered with external consultants to identify energy reduction opportunities.
Social: Enhanced diversity and inclusion efforts by adding a new employee resource group and supporting diverse college students and graduates.
Governance: Revised Code of Conduct and strengthened anti-bribery and corruption programs.
The report aligns with the Global Reporting Index and Sustainability Accounting Standards Board Index, demonstrating Integra's commitment to creating healthier people, workplaces, and world.
Integra LifeSciences (NASDAQ: IART) reported Q2 2024 financial results with revenues of $418.2 million, up 9.7% on a reported basis and 2.3% organically. The company reported a GAAP loss per share of $(0.16), compared to $0.05 in the prior year, and adjusted EPS of $0.63, down from $0.71. Integra updated its full-year 2024 guidance, projecting revenues of $1.609-$1.629 billion and adjusted EPS of $2.41-$2.57. The revised outlook reflects temporary shipping holds and investments in quality system improvements. Key highlights include:
- Early integration success with Acclarent ENT acquisition
- Plans to relaunch SurgiMend and PriMatrix at new facility in 2026
- Received PMA approvable notification for SurgiMend
- Implementing compliance master plan to address quality issues
Integra LifeSciences (Nasdaq: IART) has announced plans to restart manufacturing of PriMatrix® and SurgiMend® at its new facility in Braintree, Massachusetts, expected to be operational in the first half of 2026. The company has decided to consolidate operations at the new Braintree site instead of restarting production at its Boston facility. This decision follows a reassessment of plans after receiving third-party audit findings for the Boston site in March.
The new 100,000 square foot state-of-the-art facility in Braintree offers advantages such as improved quality systems, efficient process flows, and capacity for future growth. Integra will temporarily use the Boston site for product and process development to support the transition. The company remains committed to bringing PriMatrix and SurgiMend back to market and achieving pre-market approval for SurgiMend PRS in implant-based breast reconstruction.
FAQ
What is the current stock price of Integra LifeSciences Holdings (IART)?
What is the market cap of Integra LifeSciences Holdings (IART)?
What does Integra LifeSciences Holdings Corp. specialize in?
Where is Integra LifeSciences headquartered?
What are the primary segments of Integra LifeSciences?
What recent acquisition was announced by Integra LifeSciences?
What are some of the key products offered by Integra LifeSciences?
How did Integra perform financially in the second quarter of 2023?
What is the purpose of Integra’s CereLink ICP Monitoring System?
How many employees does Integra LifeSciences have?
Which markets does Integra LifeSciences serve?
What is Integra’s strategy for growth in 2024?
